Renal Cell Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
Conditions: Prostate Cancer; Oligoprogressive; Urothelial Carcinoma; Renal Cell Carcinoma Interventions: Device: Ablative local therapy Sponsors: University of California, Davis; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Conditions: Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Melanoma Interventions: Biological: Pembrolizumab co-formulated with hyaluronidase; Biological: Pembrolizumab Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials

Delving Into Participation Trends in Renal Cell Carcinoma Studies
Conditions: Renal Cell Carcinoma Sponsors: Power Life Sciences Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2023 Category: Research Source Type: clinical trials

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Conditions: Advanced Solid Tumor; CDKN2A; NSCLC; Urothelial Carcinoma Bladder; Melanoma; Pancreas Adenocarcinoma; HNSCC; Renal Cell Carcinoma; Mesothelioma; Gastric Cancer Interventions: Drug: Milademetan; Drug: Atezolizumab Sponsors: Rain Oncology Inc Withdrawn (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials

89Zr-DFO-girentuximab Expanded Access Program (EAP)
Conditions: Clear Cell Renal Cell Carcinoma Interventions: Diagnostic Test: 89Zr-DFO-girentuximab Sponsors: Telix International Pty Ltd Available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials

Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
Conditions: Predictive Ability of Contrast-enhanced CT-based Deep Learning Model in Patients With Localised ccRCC; Generalisation of a Deep Learning Prediction Model in Multicentre Data; Comparison of Prediction Performance Between Deep Learning Prediction Model and Traditional Prediction Models Sponsors: Mingzhao Xiao Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2023 Category: Research Source Type: clinical trials

PET/MR for Characterization of Renal Masses (RMs)
Conditions: Renal Tumor; Renal Cell Carcinoma; Renal Tumor, Benign Interventions: Diagnostic Test: 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging Sponsors: University of Texas Southwestern Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 11, 2023 Category: Research Source Type: clinical trials

Renal Cell Arrest and Damage Biomarkers in Progression and Outcome of Septic AKI
Conditions: AKI - Acute Kidney Injury Interventions: Diagnostic Test: renal cell arrest and damage biomarkers assessment Sponsors: Alexandria University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials

Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer
Conditions: Metastatic Clear Cell Renal Cell Carcinoma; With Positive PSMA Expression at Tumor Sites Interventions: Drug: 177Lu-PSMA-1 (radiopharmaceutical) Sponsors: Centre Leon Berard Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials

Moesin Expression in Clear Cell Renal Cell Carcinoma
Condition: Renal Cell Carcinoma Intervention: Genetic: Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma Sponsor: Sohag University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Moesin Expression in Clear Cell Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma Interventions: Genetic: Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma Sponsors: Sohag University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Condition: Renal Cell Carcinoma Interventions: Drug: Tivozanib; Drug: Nivolumab Sponsors: M.D. Anderson Cancer Center; AVEO Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma Interventions: Drug: Tivozanib; Drug: Nivolumab Sponsors: M.D. Anderson Cancer Center; AVEO Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials